Biologic Treatments for Asthma and Chronic Obstructive Pulmonary Disorder
The global COVID-19 pandemic has brought respiratory disease to the forefront of public health, but asthma prevalence has been rising globally for decades. Asthma is mediated by errant immune activation and airway remodeling, but the influences of environment, nutrition, and comorbidities (e.g., ast...
Main Authors: | Misa Kusumoto, Bryan J. Mathis |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-04-01
|
Series: | Allergies |
Subjects: | |
Online Access: | https://www.mdpi.com/2313-5786/1/2/7 |
Similar Items
-
Prevalence of asthma—chronic obstructive pulmonary disease overlap in patients with airflow limitation
by: Ahmed Youssef Shabaan, et al.
Published: (2021-01-01) -
Role of biologics in severe eosinophilic asthma – focus on reslizumab
by: Pelaia G, et al.
Published: (2016-07-01) -
Characteristics of asthma–chronic obstructive pulmonary disease overlap among chronic obstructive pulmonary disease and asthma patients: Based on one center cross-sectional study
by: Onur Turan, et al.
Published: (2021-01-01) -
A comparison of biologicals in the treatment of adults with severe asthma – real-life experiences
by: Emma Kotisalmi, et al.
Published: (2020-05-01) -
Airflow obstruction: is it asthma or is it COPD?
by: Rogliani P, et al.
Published: (2016-11-01)